Matt Lamkin reports via Scientific American: In March, the Food and Drug Administration approved esketamine, a drug that produces psychedelic effects, to treat depression — the first psychedelic ever to clear that bar. Meanwhile the FDA has granted “breakthrough therapy” status — a designation that enables fast-tracked research — to study MDMA (also called “ecstasy”) as a treatment for post-traumatic stress…